Analyst Conference Summary

Illumina
ILMN

conference date: August 5, 2021 @ 2:00 PM Pacific Time
for quarter ending: June 30, 2021 (second quarter, Q2 2021)


Forward-looking statements

Overview: OOPS! The data on this page got erased. Consult the company website, as it is not worth it to me to recreate the page at this point. -- William Meyers

Basic data (GAAP):

Revenue was $ billion, a record, up % sequentially from $1.13 billion and up % from $ million in the year-earlier quarter.

Net income was $ million, up % sequentially from $185 million, and up % from $ million year-earlier.

Diluted EPS was $, up % sequentially from $1.26, and up 325% from $ year-earlier.

Guidance:

Conference Highlights:

Francis deSouza, President and CEO, said ""

In Q2 2021 announced a partnership with Kartos Therapeutics for comprehensive genomic profiling for blood cancers. Received Emergency Use Authorization from the U.S. FDA for COVIDSeq on NextSeq 2000, expanding COVID-19 diagnostic testing and surveillance capabilities for mid- and high-throughput laboratories.

In Q3 2021 sequencing consumables revenue of $ million was up % year-over-year, driven by demand in both Clinical and Research segments. Oncology testing recorded its third consecutive quarter of outstanding year-over-year growth as customers announced additional offerings for therapy selection and MRD tests.

Non-GAAP numbers: net income $ million, down 1% sequentially from $276 million, and up % from $ million year-earlier. Diluted EPS was $, down % sequentially from $1.87, and up % from $ year-earlier.

Cash, equivalents and investment balance was $ billion, down sequentialy from $ billion. Long term debt $ billion. Cash flow from operations was $253 million. Free cash flow was $ million. Capital expenditures were $ million. Cash used to repurchase stock was $0 million.

Product revenue was $ million, services $ million.

GAAP cost of revenue was million, leaving gross profit of $ million. Operating expenses were $ million, consisting of: $ million for research and development; $ million for selling, general, and administrative. Leaving income from operations of $ million. Other income was $ million. Income tax provision $ million.

Q&A selective summary:

ILMN main page

OpenIcon Analyst Conference Summaries Main Page

 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BMY
 CLDX
 CLSN
 DRNA
 EPZM
 GILD
 GLYC
 IMGN
 INCY
 INO
 IONS
 ISRG
 MCHP
 MRNA
 PLX
 REGN
 RNA
 SAGE
 SGEN
 SYRS
 VBLT
 VSTM
 WBA

       

Disclaimer: My analyst call summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. This is journalism, not advice.

Copyright 2021 William P. Meyers